Summary.-A series of consecutive unselected patients with primary breast carcinoma and their age-matched controls were studied for serum CEA in relation to clinical findings. Raised CEA was found in a similar frequency in patients with primary breast cancer (pre-and postoperative) and in the control women: 16%, 11% and 110%, respectively, exceeded the selected upper limit of the reference range (13 ng/ml) with a double-antibody radioimmunoassay. In the breast-cancer patients, however, 48% of the raised CEA levels exceeded 16 ng/ml, compared with only 20% in the controls. Significant correlations (r,0-3) were found between CEA levels and tumour size, TNM classification and a combined clinical and histopathological classification. A high frequency of raised CEA values in the advanced breast-cancer patients was the essential contribution to these positive correlations. A correlation coefficient of 0-6 was found between pre-and postoperative CEA values. The frequency of smoking and/or chronic disease was unexpectedly high in patients as well as in controls with high CEA.
RAISED levels of carcinoembryonic antigen (CEA) can be demonstrated not only in patients with malignant tumours (Gold et al., 1973; Hansen et al., 1974) but also in some patients with benign disease and in healthy persons. In advanced breast cancer raised levels of CEA are reported at a frequency of about 70-80% (Chu & Nemoto, 1973; Steward et al., 1974; Tormey et al., 1975; Wang et al., 1975; Lamerz & Ruider, 1976; Tormey et al., 1977) . In primary breast cancer raised CEA values are reported in frequencies from 0%0 in locally confined cancers (Lamerz & Ruider, 1976) to 55%/ in a series of operable but otherwise undefined cancers (Borthwick et al., 1977) . The differences between the results of the various studies probably depend on the composition of the patient groups and also on the criteria for CEA elevation. In some studies (Steward et al., 1974; Wahren et al., 1978) CEA levels have been shown to correlate with the stage of the disease according to a clinical classification as with CEA in colonic carcinoma (Zamcheck et al., 1975) .
Pre-treatment and post-treatment CEA levels have been studied in a few series of primary breast cancer (Wang et al., 1975; Tormey et al., 1977; Wahren et al., 1978) . In the study of Wang et al. (1975) a postoperatively raised CEA level indicated faster recurrence, whilst preoperative CEA levels did not correlate with the recurrence rates. In earlier studies, the patients (or patient materials) were selected and the advanced stages were very often over-represented. When controls were examined they were usually not matched for age or sex.
The The patients answered a questionnaire concerning among other things, smoking habits and earlier and current diseases. This information was checked against the hospital records. Blood samples (without additives) for analysis of CEA in serum were drawn before and after surgery. The first blood sample was taken after admission to hospital but before surgery and the second 10 days to 26 weeks after surgery, the median interval being 3 weeks. Three quarters of the samples were taken less than 6 weeks after surgery. In the patient group, serum was available for analysis of CEA in 147 patients preoperatively and in 168 patients postoperatively. The difference from the total of 179 was due to a lack of serum in some cases, and there was no indication of any systematic selection of these patients.
Controls.-Each breast-cancer patient had an age-matched control without a history of breast cancer. The controls were selected from a computerized population register and the age-matching was within the range of 3 days. Twenty-five of the primarily selected controls refused participation or were inaccessible and had to be replaced by alternative controls. This was done in a way to minimize the risk of affecting the results, according to a method described by Adami & Vegelius (1978) .
All controls answered a questionnaire identical to that for the patient group. In addition, they were all clinically examined, especially to exclude breast carcinoma, and blood samples were drawn. Serum for analysis of CEA was available from 174 control women.
CEA radioimmunoassay.-The sera of patients and controls were directly sent to the investigators, immediately frozen and stored at -90W. A detailed comparison to the RIA of Hoffman-La Roche was made twice (Wahren et al., 1975; Zimmerman, 1978) . The normal value was slightly higher than in the Roche test and comparable to that of other double-antibody assays (Laurence et al., 1972) . The results in evaluating raised CEA were similar to that obtained with the Roche assay (Wahren et al., 1975) and also to the original RIA of Gold et al. (1973) .
A double-antibody radioimmunoassay was performed. 0-2 ml of a patient's serum or a predetermined CEA amount was mixed with 0-1 ml of absorbed diluted rabbit anti-CEA serum in phosphate-buffered saline (PBS) with 1% bovine serum albumin (BSA) and incubated for 6 h at 37°C. To a dilution of antiserum precipitating 65% of maximum precipitable labelled CEA, 0-1 ml of 125J-CEA was added. Labelling was performed by a modified chloramine-T method (Hunter, 1971) . The mixture was incubated overnight at room temperature. Thereafter, 1 ml of cellulose-bound sheep-anti-rabbit IgG diluted 1: 50 (Organon, Oss, Holland) was added, followed by incubation for 2 h at 37W with intermittent agitation. The sedimentation of antigen-antibody complexes was achieved by low-spread centrifugation, 1000 g for 5 min. After one wash in PBS the pellet was counted and the percentage of 125I-CEA binding was calculated. Perchloric acid (PCA) extraction of the sera before assay made no difference to the CEA values.
All the serum assays were performed in a few consecutive assays to keep variation low (Zimmerman, 1978) . The intra-assay variation was 5%, the inter-assay variation 10%.
The lowest detectable dose was 0-2 ng CEA.
Values exceeding 13 ng/ml (mean value of normal persons +1 s.d.) were considered above normal. Immunologically cross-reacting substances other than CEA may interfere in both assays, although NCA (non-specific crossreactive antigen) has to be present in Hg amounts to cause inhibitionl (Gadler et al., 1978) . The intactness of serum proteins of the stored sera was controlled by IgG and IgM quantification with Tripartigen immunodiffusion plates (Behringwerke, MarburgLahn, Germany) and only sera with levels above the lower normal limit were evaluated.
RESULTS
The distributions of CEA values in breast-cancer patients before and after surgery and in controls are presented in Fig. 2 -13 -9 -7I5 -3 -)1 1I .37 +9 can also be seen in Table II that 48% (11/23) of the patients with raised CEA (> 13 ng/ml) had a value > 16 ng/ml, while the corresponding figure for the control group was 20% (4/20).
The difference between the patient's CEA value pre-and postoperatively and in the corresponding age-matched control woman was calculated. Fig. 3 shows the distribution of these differences. The differences between pre-and postoperative values for each patient are also shown. All histograms indicate essentially a normal distribution with the mean difference near to 0.
In the different TNM stages values > 13 ng/ml were found preoperatively in 10% in Stage I, 15% in Stage II, 31% in Stage III and 50% in Stage IV. Postoperatively, the corresponding frequencies were 8 %, 7 %, 21% and 50% respectively (Table II) .
In all stages, except IV, the mean posttreatment values were somewhat lower than the pre-treatment levels. A raised CEA occurred preoperatively as well as postoperatively in 9 patients: 3 in Stage IV, 2 I in 5. The postoperative value was omitted in only one case (Stage II).
In Table III the mean CEA value is shown for the different TNM stages, for different tumour diameters according to the T-classification of the TNM system, and for the different groups according to the clinico-histopathological classification. Most mean values among the controls corresponding to the patients in the different patient groups were between 10 and 11 ng/ml. In TNM stages I-III, T classification TO-T3 and Stages 0-III of the clinicohistopathological classification, the mean values were all below 13 ng/ml. There was a tendency to higher mean values in Stage II and in T3 tumours. In Stage IV and in T4 tumours the mean values of CEA were all > 13 ng/ml and significantly higher (P<0 05) than in Stages I-III and T1-T3, respectively.
In Table IV (Martin etal., 1976; Onizawa et al., 1976) . Smoking is also reported to give raised values of CEA to a frequency of about 20% in the absence of malignant disease (Hansen et al., 1974) . In control groups of other investigators, raised CEA values are reported in frequencies from 0% (Laurence et al., 1972) to 42% (Onizawa et al., 1976) . In our control group the raised values could be explained by smoking or chronic disease in all but 4 cases. In the patient group, 24/32 women with elevated CEA were smokers or had severe non-malignant diseases. In these cases it is impossible to decide whether the raised CEA level is unspecific or due to the malignant disease.
The most interesting finding in the present study was that about the same frequency of breast cancer patients and age-matched controls had raised CEA values, although values above 16 ng/ml were more frequent in the patient group. Wang et al. (1975) found a similar frequency of raised CEA values in normal women and in women with early breast cancer pre-and postoperatively, but in other investigations (Laurence et al., 1972; Hansen et al., 1974; Onizawa et al., 1976; Borthwick et al., 1977 ) the controls had a lower frequency of raised levels than the breast-cancer patients. The disagreement between previous investigations may not only be due to different distributions with respect to the stage of the disease but also to a different composition of the control groups. In our unselected series of patients with breast cancer and in age-matched controls it seems evident that factors other than cancer are important for the level of CEA. This statement is based on the high frequency of smokers and sufferers from chronic diseases known to give raised CEA values. An exception is Stage IV cancer. A high frequency of raised CEA values in advanced breast cancer is verified in several studies (e.g. Martin et al., 1976; Neville, 1976) .
The significant correlations in the present study between CEA and clinical classification can mainly be explained by the strong influence of a few high CEA values in advanced carcinomas. The same seems to be the case in studies by Steward et al. (1974) and Wahren et al. (1978) but not in the study of Lamerz & Ruider (1976) . The finding of raised CEA values in carcinoma in an advanced stage is at present of little direct clinical importance for the treatment. It may become of interest in assessing indications for adjuvant therapy and in the study of the biology of tumour-cell populations.
The relationship between pre-and postoperative CEA levels has been studied earlier, but without conclusive results. Wang et al. (1975) reported that high postoperative CEA levels often indicated early recurrence, but this remains to be verified in larger series. We found a correlation coefficient of about 0-6 between pre-and postoperative values. In the present series it is too early to evaluate any possible relationship between raised pre-and postoperative CEA values and the frequency of and interval before recurrence. Of 5 patients classified as TNM stage I or II and with elevated CEA levels, 3 succumbed from causes other than breast cancer within 18-24 months postoperatively (Table V) . Further follow-up of the patients as well as the controls may give interesting information.
